How to buy XTL Biopharmaceuticals stock

XTL Biopharmaceuticals Ltd is a biotechnology business based in the US. XTL Biopharmaceuticals shares (XTLB) are listed on the NASDAQ and all prices are listed in US Dollars.

XTL Biopharmaceuticals share price

Use our graph to track the performance of XTLB stocks over time.

XTL Biopharmaceuticals shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$0.63 - $4.17
50-day moving average	$3.41
200-day moving average	$2.64
Wall St. target price	$30.00
PE ratio	9.5835
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.20

Buy XTL Biopharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy XTL Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of XTL Biopharmaceuticals Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is XTL Biopharmaceuticals under- or over-valued?

Valuing XTL Biopharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XTL Biopharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

XTL Biopharmaceuticals's P/E ratio

XTL Biopharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, XTL Biopharmaceuticals shares trade at around 10x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

XTL Biopharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-8.06%
Return on equity TTM	-29.71%
Profit margin	0%
Book value	$1.20
Market capitalisation	$18.7 million

TTM: trailing 12 months

Shorting XTL Biopharmaceuticals shares

There are currently 28,167 XTL Biopharmaceuticals shares held short by investors – that's known as XTL Biopharmaceuticals's "short interest". This figure is 460.1% up from 5,029 last month.

There are a few different ways that this level of interest in shorting XTL Biopharmaceuticals shares can be evaluated.

XTL Biopharmaceuticals's "short interest ratio" (SIR)

XTL Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of XTL Biopharmaceuticals shares currently shorted divided by the average quantity of XTL Biopharmaceuticals shares traded daily (recently around 31296.666666667). XTL Biopharmaceuticals's SIR currently stands at 0.9. In other words for every 100,000 XTL Biopharmaceuticals shares traded daily on the market, roughly 900 shares are currently held short.

However XTL Biopharmaceuticals's short interest can also be evaluated against the total number of XTL Biopharmaceuticals shares, or, against the total number of tradable XTL Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XTL Biopharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 XTL Biopharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable XTL Biopharmaceuticals shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against XTL Biopharmaceuticals.

Find out more about how you can short XTL Biopharmaceuticals stock.

XTL Biopharmaceuticals share dividends

We're not expecting XTL Biopharmaceuticals to pay a dividend over the next 12 months.

Have XTL Biopharmaceuticals's shares ever split?

XTL Biopharmaceuticals's shares were split on a 1:5 basis on 9 February 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XTL Biopharmaceuticals shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for XTL Biopharmaceuticals shares which in turn could have impacted XTL Biopharmaceuticals's share price.

XTL Biopharmaceuticals share price volatility

Over the last 12 months, XTL Biopharmaceuticals's shares have ranged in value from as little as $0.625 up to $4.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XTL Biopharmaceuticals's is 0.7603. This would suggest that XTL Biopharmaceuticals's shares are less volatile than average (for this exchange).

XTL Biopharmaceuticals overview

XTL Biopharmaceuticals Ltd. , a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd.

Frequently asked questions

What percentage of XTL Biopharmaceuticals is owned by insiders or institutions?
Currently 19.947% of XTL Biopharmaceuticals shares are held by insiders and 8.678% by institutions. When does the fiscal year end for XTL Biopharmaceuticals?
XTL Biopharmaceuticals's fiscal year ends in December. Where is XTL Biopharmaceuticals based?
XTL Biopharmaceuticals's address is: 5 Badner Street, Ramat Gan, Israel, 5218102 What is XTL Biopharmaceuticals's ISIN number?
XTL Biopharmaceuticals's international securities identification number is: US98386D3070 What is XTL Biopharmaceuticals's CUSIP number?
XTL Biopharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98386D109